Eli Lilly and Company LLY
- Market cap
- $1.11T
- P/E
- 39.7×
Follow LLY
Eli Lilly and Company (LLY) EV/Sales
As of 25 September 2026, Eli Lilly and Company (LLY) trades at a EV/Sales of 13.8×. Over the past ten years it has ranged from 3.6× (December 2016) to 23.5× (June 2024); the current reading is higher than 77% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Annual
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 15.3× | (4.28%) |
| FY2024 | 16.0× | (0.73%) |
| FY2023 | 16.1× | 34.24% |
| FY2022 | 12.0× | 29.21% |
| FY2021 | 9.3× | 37.42% |
| FY2020 | 6.8× | 11.64% |
| FY2019 | 6.1× | 7.98% |
| FY2018 | 5.6× | 23.28% |
| FY2017 | 4.6× | 18.94% |
| FY2016 | 3.8× | (17.80%) |
Quarterly
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 14.0× | 17.93% |
| Mar 2026 | 11.9× | (22.52%) |
| Dec 2025 | 15.3× | 26.38% |
| Sep 2025 | 12.1× | (12.23%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.4× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.6× |
| MRK Merck & Co., Inc. compare | 6.2× |
| JNJ Johnson & Johnson compare | 6.8× |
| GILD Gilead Sciences, Inc. compare | 6.9× |
| AMGN Amgen Inc. compare | 7.0× |
| ABBV AbbVie Inc. compare | 8.3× |
| LLY Eli Lilly and Company | 13.8× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.2× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on LLY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement